Merus N.V. Share

Merus N.V. is a clinical-stage oncology company focused on developing innovative bispecific antibody therapeutics for cancer treatment. The company's proprietary Biclonics® technology platform is designed to create full-length human bispecific antibodies with optimized effector function and stability. Merus is dedicated to advancing a pipeline of novel antibody candidates with the potential to address unmet medical needs in various cancer types. Through its research and development efforts, Merus aims to deliver meaningful clinical benefits to patients and improve outcomes in the fight against cancer. The company's focus is on developing therapies that target multiple pathways involved in tumor growth, survival, and metastasis, ultimately aiming to provide more effective and durable cancer treatments.